TEST BANK for Lisa Gorski, Phillips' Man of IV
Therapeutics 8th edition
Which of the following steps are not parts of the multistage process of
carcinogenesis?
A. initiation
B. promotion
C. propagation
D. transformation - ANSWER:C
A new genetic alteration is identified in an individual patient's resected tumor. The
normal gene product appears to inhibit inappropriate cellular growth and
proliferation. Which of the following terms adequately classifies the gene?
A. proto-angiogenic gene
B. oncogene
C. tumor suppressor gene
D. DNA repair gene - ANSWER:C
A 65-year-old man is recently diagnosed with locally advanced colon cancer. The
cancer has spread to regional lymph nodes, but not distant sites. The patient
undergoes major surgery to remove the tumor. Following surgery, the patient will
receive combination chemotherapy. Which of the following best describes the
treatment?
A. adjuvant
B. curative
C. induction
D. palliative - ANSWER:A
The patient will receive oxaliplatin, fluorouracil, and leucovorin. Leucovorin is
included in the chemotherapy regimen to:
A. reduce fluorouracil toxicity
B. increase fluorouracil cytotoxicity
C. reduce oxaliplatin toxicity
D. increase oxaliplatin cytotoxicity - ANSWER:B
Which of the following toxicities is not usually associated with the EGFR inhibitor
class of anticancer agents?
A. rash
B. myelosuppression
C. hepatotoxicity
D. diarrhea - ANSWER:B
,Based on the name, what is the source of the monoclonal antibody trastuzumab?
A. murine
B. human
C. chimeric
D. humanized - ANSWER:D
Which of the following are considered risk factors for developing breast cancer?
A. Age, late menarche, early menopause.
B. Hormone replacement therapy, early menarche, early menopause.
C. Age, hormone replacement therapy, first pregnancy after age 30.
D. Hormone replacement therapy, first pregnancy after age 30, early menopause.
E. Age, first pregnancy after age 30, early menopause. - ANSWER:C
Multiple myeloma (MM) is a malignancy characterized by the overproduction of
which cell type?
A. Myeloid stem cells
B. Neutrophils
C. Plasma cells
D. Platelets - ANSWER:C
Parkinson disease (PD) is characterized by a nigrostriatal deficiency of:
A. Acetylcholine
B. Dopamine
C. Norepinephrine
D. Serotonin - ANSWER:B
The clinical diagnosis of parkinsonism is based on the presence of bradykinesia and
at least one of three other features: muscular rigidity, resting tremor, and:
A. Dystonia
B. Nystagmus
C. Postural instability
D. Seizures - ANSWER:C
Which of the following is the most effective drug for PD?
A. Amantadine
B. Carbidopa/levodopa
C. Pramipexole
D. Rasagiline - ANSWER:B
An 80-year-old with newly diagnosed PD and a history of memory problems and
confusion is best treated with:
, A. Amantadine
B. Carbidopa/levodopa
C. Trihexyphenidyl
D. Ropinirole - ANSWER:B
The mechanism of action for entacapone is:
A. COMT inhibition
B. MAO-B inhibition
C. D2-receptor inhibition
D. Dopa-decarboxylase inhibition - ANSWER:A
Which of the following will not worsen PD symptoms?
A. Haloperidol
B. Metoclopramide
C. Prochlorperazine
D. Rasagiline - ANSWER:D
A patient with PD is taking carbidopa/levodopa 25/100 mg three times a day, and
reports that he tends to slow down 2 hours before his next carbidopa/levodopa
dose. This patient is most likely experiencing:
A. Delayed onset response
B. Dyskinesia
C. Freezing
D. Wearing off - ANSWER:D
A 70-year-old patient taking carbidopa/levodopa 25/100 mg three times a day for PD
is experiencing end-of-dose wearing off. The best next step is to:
A. Add tolcapone.
B. Consider surgery.
C. Add trihexyphenidyl.
D. Increase carbidopa/levodopa to four times daily - ANSWER:D
A 63-year-old patient taking carbidopa/levodopa 25/100 mg four times a day for PD
is experiencing end-of-dose wearing off. The best recommendation is to:
A. Add tolcapone.
B. Add entacapone.
C. Consider deep-brain stimulation (DBS).
D. Change carbidopa/levodopa to three times a day. - ANSWER:B
A 72-year-old patient with moderate-severe PD was placed on carbidopa/levodopa
25/100 mg three times a day by his primary care physician. He is complaining of
Therapeutics 8th edition
Which of the following steps are not parts of the multistage process of
carcinogenesis?
A. initiation
B. promotion
C. propagation
D. transformation - ANSWER:C
A new genetic alteration is identified in an individual patient's resected tumor. The
normal gene product appears to inhibit inappropriate cellular growth and
proliferation. Which of the following terms adequately classifies the gene?
A. proto-angiogenic gene
B. oncogene
C. tumor suppressor gene
D. DNA repair gene - ANSWER:C
A 65-year-old man is recently diagnosed with locally advanced colon cancer. The
cancer has spread to regional lymph nodes, but not distant sites. The patient
undergoes major surgery to remove the tumor. Following surgery, the patient will
receive combination chemotherapy. Which of the following best describes the
treatment?
A. adjuvant
B. curative
C. induction
D. palliative - ANSWER:A
The patient will receive oxaliplatin, fluorouracil, and leucovorin. Leucovorin is
included in the chemotherapy regimen to:
A. reduce fluorouracil toxicity
B. increase fluorouracil cytotoxicity
C. reduce oxaliplatin toxicity
D. increase oxaliplatin cytotoxicity - ANSWER:B
Which of the following toxicities is not usually associated with the EGFR inhibitor
class of anticancer agents?
A. rash
B. myelosuppression
C. hepatotoxicity
D. diarrhea - ANSWER:B
,Based on the name, what is the source of the monoclonal antibody trastuzumab?
A. murine
B. human
C. chimeric
D. humanized - ANSWER:D
Which of the following are considered risk factors for developing breast cancer?
A. Age, late menarche, early menopause.
B. Hormone replacement therapy, early menarche, early menopause.
C. Age, hormone replacement therapy, first pregnancy after age 30.
D. Hormone replacement therapy, first pregnancy after age 30, early menopause.
E. Age, first pregnancy after age 30, early menopause. - ANSWER:C
Multiple myeloma (MM) is a malignancy characterized by the overproduction of
which cell type?
A. Myeloid stem cells
B. Neutrophils
C. Plasma cells
D. Platelets - ANSWER:C
Parkinson disease (PD) is characterized by a nigrostriatal deficiency of:
A. Acetylcholine
B. Dopamine
C. Norepinephrine
D. Serotonin - ANSWER:B
The clinical diagnosis of parkinsonism is based on the presence of bradykinesia and
at least one of three other features: muscular rigidity, resting tremor, and:
A. Dystonia
B. Nystagmus
C. Postural instability
D. Seizures - ANSWER:C
Which of the following is the most effective drug for PD?
A. Amantadine
B. Carbidopa/levodopa
C. Pramipexole
D. Rasagiline - ANSWER:B
An 80-year-old with newly diagnosed PD and a history of memory problems and
confusion is best treated with:
, A. Amantadine
B. Carbidopa/levodopa
C. Trihexyphenidyl
D. Ropinirole - ANSWER:B
The mechanism of action for entacapone is:
A. COMT inhibition
B. MAO-B inhibition
C. D2-receptor inhibition
D. Dopa-decarboxylase inhibition - ANSWER:A
Which of the following will not worsen PD symptoms?
A. Haloperidol
B. Metoclopramide
C. Prochlorperazine
D. Rasagiline - ANSWER:D
A patient with PD is taking carbidopa/levodopa 25/100 mg three times a day, and
reports that he tends to slow down 2 hours before his next carbidopa/levodopa
dose. This patient is most likely experiencing:
A. Delayed onset response
B. Dyskinesia
C. Freezing
D. Wearing off - ANSWER:D
A 70-year-old patient taking carbidopa/levodopa 25/100 mg three times a day for PD
is experiencing end-of-dose wearing off. The best next step is to:
A. Add tolcapone.
B. Consider surgery.
C. Add trihexyphenidyl.
D. Increase carbidopa/levodopa to four times daily - ANSWER:D
A 63-year-old patient taking carbidopa/levodopa 25/100 mg four times a day for PD
is experiencing end-of-dose wearing off. The best recommendation is to:
A. Add tolcapone.
B. Add entacapone.
C. Consider deep-brain stimulation (DBS).
D. Change carbidopa/levodopa to three times a day. - ANSWER:B
A 72-year-old patient with moderate-severe PD was placed on carbidopa/levodopa
25/100 mg three times a day by his primary care physician. He is complaining of
